Table 1.
Studies Included in the Meta-Analysis
| Study | Total no. of patients (males) | Pain stimulus | Type and dosage of cannabinoid used | Route of administration | Length of follow-up |
|---|---|---|---|---|---|
| Beaulieu32 | 30 (3) | Surgery (gynecologic [46%], orthopedic [44%], other [10%]) | Nabilone (1 or 2 mg) | Oral | 24 h |
| Buggy et al.33 | 40 (0) | Surgery (elective total abdominal hysterectomy) | THC (5 mg) | Oral | 6 h |
| Jain et al.34 | 56 (51) | Acute postoperative, trauma, or fracture pain | Levonantradol (1.5, 2, 2.5, or 3 mg) | Intramuscular | 6 h |
| Kalliomaki et al.35 | 120 (120) | Lower third molar surgical removal | AZD1940 (800 μg) | Oral | 8 h |
| Levin et al.36 | 340 (0) | Elective surgery | Nabilone (0.5 mg) | Oral | 120 min |
| Ostenfeld et al.37 | 92 (49) | Third molar tooth extraction | GW842166 (100 or 800 mg) | Oral | 10 h |
THC, Δ9-tetrahydrocannabinol.